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ountries and moreover, are not accurate enough for routine diag-
osis and needs further validation in children. Prevention of the
rogression of dormant infection plays an important role in TB con-
rol; it is performed by contact tracing using DNA ﬁngerprinting
mostly restriction fragment length polymorphism analysis [RFLP])
n both developed and less developed countries.
Serum-based antibody assays offer advantages of easy specimen
ollection and rapidity, although not sensitive or speciﬁc enough
or clinical use. Tests developed using combinations of antigens
rom proteonomics approach appear promising. Upcoming tests
ased on detection of antigens, such as lipoarabinomannan in urine
r serum samples, and cutaneous response to transdermal appli-
ation of mbp64 need further validation in children. Detection of
nterferon –  release assay have not shown any major advantage
ver Tuberculin Skin Test (TST) in terms of sensitivity and speci-
city and are more expensive. T-SPOT may discriminate between
on-TBmycobacterial diseases in children in settingswith low inci-
enceof TB;however, their role indetectionof TB inHIV-infectedor
alnourished childrenneeds further research. Reﬁnement of exist-
ng tools, development and testing of new tools, better laboratory
nfrastructure and dedicated national policy are urgently required
o improve diagnosis and treatment of PPTB in resource-poor coun-
ries.
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Pediatric tuberculosis which is considered as pauci-bacillary
s given low priority in Tuberculosis control. In resource-limited
ettings national TB control programmes focus on infectious spu-
um smear-positive cases. As result of this neglect pediatric
B is often under-diagnosed, under-treated and under-reported.
ontact-tracingwhich is routinelydone inhigh-incomecountries is
ot done in resource-limited countries. This has resulted in delayed
etection of tuberculosis among child contacts. Current standard-
zed reporting systemdoes not include indicators reﬂecting service
elivery to children.
Achieving treatment success in children relies on prompt diag-
osis and treatment initiation,with appropriate treatment regimen
weigh-based doses) and support for treatment adherence. An
mportant development in treatment of pediatric tuberculosis is
evised dosage guidelines recommending increased dosages of
rst-line drugs. But as yet no appropriate ﬁxed-dose combina-
ions and child-friendly formulations are consistent with the new
uidelines, treatmentproviders are struggling toprovidenewdoses
hrough complex interim dosing recommendations which resulted
n delayed implementation of new guidelines. The new guidelines
ave clariﬁed the role of Ethambutol in pediatric TB which wasnfectious Diseases 16S (2012) e2–e157 e65
questioned for its toxicity proﬁle, and also advised against the use
of streptomycin.
BCG vaccination only offers signiﬁcant protection against dis-
seminated disease and tuberculous meningitis in young children.
BCG vaccination is contraindicated in HIV-infected children and
those with other immune deﬁciencies. Development of novel vac-
cines with improved efﬁcacy and safety remains a major research
challenge. Children are frequently excluded fromdrug trials to pre-
vent risk posed to them and limited ﬁnancial return. However,
children should be included in the evaluation of novel TB drugs,
soon after the conclusion of initial safety and efﬁcacy studies. It is
essential to include children in safety and dose ranging studies and
also to develop child friendly formulations prior to product regis-
tration. Measures like tracing, screening and isoniazid preventive
therapy for eligible child contacts have been recommended but not
effectively implemented, since most TB programmes do not con-
sider themas priority. To tackle the emerging challenge of pediatric
tuberculosis changes and improvements in existing practices in
diagnosis and treatment are needed. Pediatric tuberculosis should
also be prioritized in National Tuberculosis Control Programs.
http://dx.doi.org/10.1016/j.ijid.2012.05.161
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Pitfall and challenges in clinical management of childhood
tuberculosis
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Children are more susceptible to TB and have higher risk of
extrapulmonary or severe forms of disease than in adults. Most
of TB in children acquired from household adults, and treatment
in adults help preventing disease in children. The common pitfalls
and challenges are:
- Diganosis: Because the clinical signs and symptoms of TB in chil-
dren are not speciﬁc and microbiologic yield is low, the diagnosis
of childhood TB is difﬁcult. Obtaining the specimens from sputum
is possible in young children and gastric aspiration is uncom-
fortable and mostly required hospitalization. None of the scoring
system is accurate. Clinical diagnosis and empirical treatment are
commonly practiced which may result in in-appropriate treat-
ment.
- Anti-tuberculous drugs: Pediatric formulation is limited avail-
able and for only rifampin. The recent pharmacokinetic study
suggested the need to increase recommended dose in children.
Recently, WHO recommended to increase INH from 5 to 10
mg/kg/day, rifampin from 10 to 15 mg/kg/day, pyrazinamide
from 25 to 35 mg/kg/day. Streptomycin is no longer recom-
mended in the ﬁrst line regimen.
- Adhering to treatment: DOT is needed but not available in most
resource-limited settings. Intermittent regimens (2-3 doses per
week) may help adherence but may reduce efﬁcacy and not rec-
ommend in HIV-infected children.
- Drug resistance: The drug susceptibility results are mostly
unavailable in children. Most of drug resistance cases were
